Can I read Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial on EtoBox?

Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial by Branislav Jeremic; Yuta Shibamoto; Ljubisa Acimovic; Biljana Milicic; Slobodan Milisavljevic; Nebojsa Nikolic; Aleksandar Dagovic; Jasna Aleksandrovic; Gordana Radosavljevic-Asic is a Medicine article available to read on EtoBox.

What is Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial about?

## Purpose: To investigate whether the addition of weekend chemotherapy consisting of carboplatin/etoposide to hyperfractionated radiation therapy (hfx rt) and concurrent daily carboplatin/etoposide offers an advantage over the same hfx rt/daily carboplatin/etoposide. ## Methods and materials: A total of 195 patients (group i, 98; group ii, 97) were treated with either hfx rt to a total tumor dose of 69.6 gy via 1.2 gy b.i.d. fractionation and daily 50 mg each of carboplatin and etoposide during the rt course (group i) or the same hfx rt with daily carboplatin/etoposide consisting of 30 mg each of carboplatin and etoposide and with weekend (saturdays and sundays) 100 mg each of carboplatin and etoposide during the rt course (group ii). ## Results: No difference was found regarding median survival time and 5-year survival rates (20 vs. 22 months and 20% vs. 23%; p = 0.57). median time to local progression was 20 and 19 months, respectively, while 5-year local progression-free survival rates were 28% and 27%, respectively (p = 0.66). also, there was no difference regarding either median time to distant metastasis and 5-year distant metastasis-free survival (21 vs. 25 months and 29% v

Who reads Hyperfractionated radiation therapy and concurrent low-dose, daily carboplatin/etoposide with or without weekend carboplatin/etoposide chemotherapy in stage III non-small-cell lung cancer: a randomized trial?

Author

Branislav Jeremic; Yuta Shibamoto; Ljubisa Acimovic; Biljana Milicic; Slobodan Milisavljevic; Nebojsa Nikolic; Aleksandar Dagovic; Jasna Aleksandrovic; Gordana Radosavljevic-Asic

Publisher

Elsevier Science; Elsevier ; Elsevier BV (ISSN 0360-3016)

Published

2001

Language

EN

Field

Medicine (Health Sciences)